comparemela.com

Latest Breaking News On - Duke cancer institute center - Page 1 : comparemela.com

Study Data Shows Potential of Gene Signatures to Predict Treatment Response in Patients With Recurrent Prostate Cancer

The research was aided by the Decipher Genomics Resource for Intelligent Discovery, which helped derive the gene signatures used during the analysis.

Andrew armstrongElai davicioniDuke cancer institute centerDecipher genomics resourceIntelligent discoveryUrologic cancers

Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

New data are from a retrospective analysis of the Phase 2 STREAM trial .

United statesSouth san franciscoAndrew armstrongElai davicioniResearch useDuke universityVeracyte incDuke cancer institute centerDecipher genomics resourceIntelligent discoveryUrologic cancersResearch use onlyAnnual reportQuarterly reportFor research use only

Adding Olaparib to Abiraterone Does Not Worsen HRQoL in mCRPC

Investigators studied health-related quality of life (HRQoL) and pain outcomes for patients with metastatic prostate cancer (mCRPC) taking olaparib plus abiraterone.

North carolinaUnited statesAndrewj armstrongMerck sharp dohmeAmerican society of clinical oncologyDuke cancer institute centerAmerican societyClinical oncologyUrologic cancerFunctional assessmentCancer therapyProstate cancerBrief pain inventory short formMerck sharp

Adding Olaparib to Abiraterone Does Not Worsen HRQoL in mCRPC

Investigators studied health-related quality of life (HRQoL) and pain outcomes for patients with metastatic prostate cancer (mCRPC) taking olaparib plus abiraterone.

United statesNorth carolinaAndrewj armstrongDuke cancer institute centerAmerican society of clinical oncologyAmerican societyClinical oncologyUrologic cancerFunctional assessmentCancer therapyProstate cancerBrief pain inventory short form

New drug combo shows promise against prostate cancer in trials

In a phase 3 clinical trial by Pfizer, treatment with talazoparib and enzalutamide lowered the risk of prostate cancer progression or death by 37%.

Andrewj armstrongCoran sternbergScottt tagawaNicholas zorkoDuke cancer institute centerMasonic cancer centerUniversity of minnesotaUrologic cancersWeill cornell medicineMedical news today

vimarsana © 2020. All Rights Reserved.